Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050271 · ClinicalTrials.gov registry record · NA
Acetyl-L-Carnitine for the Treatment of NRTI-Associated Peripheral Neuropathy
A NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- NA
- Development phase
- 27
- Enrollment target
NCT00050271 is a NA study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 27 participants.
The verdict
NCT00050271, a NA study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if acetyl-L-carnitine (ALC) reduces pain, numbness, and tingling in the feet and legs of patients with nucleoside reverse transcriptase inhibitor (NRTI)-associated peripheral neuropathy. Another purpose is to determine if ALC is safe and tolerable in HIV patients who have taken certain anti-HIV drugs.
Interventions
- DRUG Acetyl-L-carnitine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Est. Completion | 2007-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00050271
The ClinicalTrials.gov registry entry for NCT00050271 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Acetyl-L-carnitine is the first listed.
NCT00050271 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00050271 about?
NCT00050271 is a clinical study titled "Acetyl-L-Carnitine for the Treatment of NRTI-Associated Peripheral Neuropathy". The purpose of this study is to determine if acetyl-L-carnitine (ALC) reduces pain, numbness, and tingling in the feet and legs of patients with nucleoside reverse transcriptase inhibitor (NRTI)-associated peripheral neuropathy. Another purpose is to determine if ALC is safe and tolerable in HIV pat...
What is the current status of trial NCT00050271?
This trial is currently completed. It is a NA study. The enrollment target is 27 participants. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00050271?
The interventions under investigation include: Acetyl-L-carnitine (DRUG).
Who is sponsoring clinical trial NCT00050271?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.